@article{bba823df784c4fff87df3e99e4e589b6,
title = "Using Circulating Tumor DNA for Colon Cancer Adjuvant Therapy: To Be or Not to Be?",
abstract = "Detection of circulating tumor DNA (ctDNA) postoperatively is prognostic for recurrence for patients with stage III colon cancer. Those with sustained undetectable ctDNA will likely be cured. Eradication of minimal residual disease (per ctDNA clearance) with chemotherapy did not occur in most ctDNA-positive patients and led to eventual disease relapse.",
author = "Morris, {Van K.} and George, {Thomas J.}",
note = "Funding Information: V.K. Morris reports other support from BioNTech, Pfizer, Bristol Myers Squibb, EMD Serono, and Novartis outside the submitted work; in addition, V.K. Morris is the principal investigator for the NRG GI-005 phase II/III trial evaluating circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with stage IIA colon cancer. T.J. George reports personal fees from Tempus and Pfizer; and nonfinancial support from Merck, AstraZeneca/MedImmune, Lilly, Bayer, Incyte, Ipsen, Seattle Genetics, Genentech, Astellas Pharma, BioMed Valley Discoveries, and GlaxoSmithKline outside the submitted work. No other disclosures were reported. Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",
year = "2022",
month = feb,
day = "1",
doi = "10.1158/1078-0432.CCR-21-3564",
language = "English (US)",
volume = "28",
pages = "438--440",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",
}